Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Roman Gulati

Showing results (111-120 of 154) with videos related to

Pageof 16
Sort By:
The Journal of Urology|January 9, 2023
Reply by AuthorsMichael T Schweizer, Lawrence True, Roman Gulati, et al.
Oncotarget|October 11, 2014
Characterization of single disseminated prostate cancer cells reveals tumor cell heterogeneity and identifies dormancy associated pathwaysLisly Chéry, Hung-Ming Lam, Ilsa Coleman, et al.
Plos One|October 31, 2014
Prostate cancer characteristics associated with response to pre-receptor targeting of the androgen axisElahe A Mostaghel, Andrew Morgan, Xiaotun Zhang, et al.
Cell Reports|May 28, 2020
Combined TP53 and RB1 Loss Promotes Prostate Cancer Resistance to a Spectrum of Therapeutics and Confers Vulnerability to Replication StressMichael D Nyquist, Alexandra Corella, Ilsa Coleman, et al.
JCO Precision Oncology|January 9, 2023
Internet-Based Germline Genetic Testing for Men With Metastatic Prostate CancerHeather H Cheng, Alexandra O Sokolova, Roman Gulati, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|November 14, 2024
PET-Based TheraP Eligibility and Outcomes of VISION-Eligible Patients with Metastatic Castration-Resistant Prostate Cancer Who Received <sup>177</sup>Lu-PSMA-617: Importance of <sup>18</sup>F-FDG-Avid Discordant FindingsRidvan Arda Demirci, Alireza Ghodsi, Roman Gulati, et al.
Journal of the National Cancer Institute|November 20, 2024
Projected outcomes of reduced-biopsy management of Grade Group 1 prostate cancer: implications for relabelingYibai Zhao, Roman Gulati, Zhenwei Yang, et al.
European Urology|June 23, 2019
Durable Response of Enzalutamide-resistant Prostate Cancer to Supraphysiological Testosterone Is Associated with a Multifaceted Growth Suppression and Impaired DNA Damage Response Transcriptomic Program in Patient-derived XenograftsHung-Ming Lam, Holly M Nguyen, Mark P Labrecque, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 21, 2016
Characterization of an Abiraterone Ultraresponsive Phenotype in Castration-Resistant Prostate Cancer Patient-Derived XenograftsHung-Ming Lam, Ryan McMullin, Holly M Nguyen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 11, 2013
Targeted androgen pathway suppression in localized prostate cancer: a pilot studyElahe A Mostaghel, Peter S Nelson, Paul Lange, et al.
Pageof 16

Showing results (111-120 of 154) with videos related to

Sort By:
Pageof 16
The Journal of Urology|January 9, 2023
Reply by AuthorsMichael T Schweizer, Lawrence True, Roman Gulati, et al.
Oncotarget|October 11, 2014
Characterization of single disseminated prostate cancer cells reveals tumor cell heterogeneity and identifies dormancy associated pathwaysLisly Chéry, Hung-Ming Lam, Ilsa Coleman, et al.
Plos One|October 31, 2014
Prostate cancer characteristics associated with response to pre-receptor targeting of the androgen axisElahe A Mostaghel, Andrew Morgan, Xiaotun Zhang, et al.
Cell Reports|May 28, 2020
Combined TP53 and RB1 Loss Promotes Prostate Cancer Resistance to a Spectrum of Therapeutics and Confers Vulnerability to Replication StressMichael D Nyquist, Alexandra Corella, Ilsa Coleman, et al.
JCO Precision Oncology|January 9, 2023
Internet-Based Germline Genetic Testing for Men With Metastatic Prostate CancerHeather H Cheng, Alexandra O Sokolova, Roman Gulati, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|November 14, 2024
PET-Based TheraP Eligibility and Outcomes of VISION-Eligible Patients with Metastatic Castration-Resistant Prostate Cancer Who Received <sup>177</sup>Lu-PSMA-617: Importance of <sup>18</sup>F-FDG-Avid Discordant FindingsRidvan Arda Demirci, Alireza Ghodsi, Roman Gulati, et al.
Journal of the National Cancer Institute|November 20, 2024
Projected outcomes of reduced-biopsy management of Grade Group 1 prostate cancer: implications for relabelingYibai Zhao, Roman Gulati, Zhenwei Yang, et al.
European Urology|June 23, 2019
Durable Response of Enzalutamide-resistant Prostate Cancer to Supraphysiological Testosterone Is Associated with a Multifaceted Growth Suppression and Impaired DNA Damage Response Transcriptomic Program in Patient-derived XenograftsHung-Ming Lam, Holly M Nguyen, Mark P Labrecque, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 21, 2016
Characterization of an Abiraterone Ultraresponsive Phenotype in Castration-Resistant Prostate Cancer Patient-Derived XenograftsHung-Ming Lam, Ryan McMullin, Holly M Nguyen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 11, 2013
Targeted androgen pathway suppression in localized prostate cancer: a pilot studyElahe A Mostaghel, Peter S Nelson, Paul Lange, et al.
Pageof 16